E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Unexplained miscarriage and how this may relate to the quality of the sperm DNA at conception, with particular emphasis on chromatin structure and DNA fragmentation and whether this may be improved by male dietary supplementation. |
|
E.1.1.1 | Medical condition in easily understood language |
Whether some unexplained miscarriage is caused by reversible problems with the man's sperm that can simply be corrected by taking a food supplement. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Male diseases of the urinary and reproductive systems [C12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10065877 |
E.1.2 | Term | Dietary and nutritional therapies |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principal question in this research is to study the feasibility, compliance and tolerance of recruiting the male partner, in couples with recurrent unexplained pregnancy loss, to a trial of dietary supplementation.
The overarching aim our research is to improve sperm DNA quality in men of couples that have suffered recurrent, unexplained pregnancy loss. This will be achieved using a dietary supplement of minerals and antioxidants given to the men, which we hypothesise should improve sperm DNA quality, this in turn may result in a reduction in the number of miscarriages and thus an increase in successful live births.
|
|
E.2.2 | Secondary objectives of the trial |
Secondary questions relate to the subsequent trial should the pilot be successful, but we would be interested to observe changes in a number of observed measures that we could examine in a later trial. These include sperm parameters; ongoing clinical pregnancy at 12 weeks and other details related to the couple's baseline health. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
>2 Unexplained miscarriages
In order to determine whether a male patient is eligible for the study sperm DNA damage will be assessed by the TUNEL assay from the baseline semen sample they provide. If the patient sample has elevated DNA damage they will be considered eligible from a baseline semen sample perspective. |
|
E.4 | Principal exclusion criteria |
Couple not naturally conceiving Couple have a diagnosed cause of repetitive miscarriage Male partner is a smoker
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The success of the feasibility study will be assessed by criteria related to the feasibility measurements to ascertain if a larger study is feasible in its current format, needs modification or is unfeasible, and includes recruitment, adherence, follow-up and withdrawal measures.
Feasibility outcomes Proportion of screened men that are eligible for the trial on the basis of their baseline sperm sample Proportion of eligible couples randomised Proportion of potentially eligible men who consent to baseline sperm sample provision Proportion of randomised men that return for their 1 month and 3 month follow-up visits for additional sperm sample provision Men’s compliance to taking the daily nutritional supplement and reasons for stopping taking the trial intervention early Proportion of couples that withdraw from the trial, and the reasons for this Proportion of couple that are lost to follow-up |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
3 months post-randomisation |
|
E.5.2 | Secondary end point(s) |
Mechanistic monitoring Amount of sperm DNA damage relative to baseline after 1 month on the trial intervention Changes in conventional sperm parameters after 1 month on the trial intervention Amount of sperm DNA damage relative to baseline after 3 months on the trial intervention Changes in conventional sperm parameters after 3 months on the trial intervention Clinical monitoring Ongoing pregnancy at 12 completed weeks of gestation Spontaneous conception rates whilst man is taking the treatment Adverse events related to the trial intervention Acceptability and impact on patients (outcome) All men will be requested to complete a short questionnaire at their 3 month follow-up visit to assess: How the trial impacted on their day-to-day life, including the attendance of follow-up visits. The acceptability of taking the daily nutritional supplement. Suggestions for making improvements to the recruitment processes. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
12 completed weeks of gestation for those couples that achieve pregnancy. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial will be four weeks after the last data capture. This will allow sufficient time for the completion of protocol procedures, data collection and data input. The BCTU trial team will notify the main REC, and RGT within 90 days of the end of trial. Where the trial has terminated early, the Trials Office will inform REC and MHRA within 15 days of the end of trial. The Trials Office will provide them with a summary of the clinical trial report within 12 months of the end of trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 28 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 28 |